Start 30 days free, no card. Full Pro access for a month, then decide. Start free

Back to analysts list

Analyst

Matthew Gillmor

KeyBanc Capital Markets · covers Healthcare

Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q3 (8 quarters).

Questions
21on tracked calls
Challenge rate
0%none of 21 questions
Companies
4questioned at least once
Reporting periods
8with questions

These figures cover the whole profile: every tracked question, all reporting periods.

How to read these numbers

Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.

Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.

No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.

Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.

Small samples. Profiles with fewer than 10 questions are marked Limited sample.

Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.

Questions asked

Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.

Showing 21 of 21 questions from 4 companies

UHSUniversal Health Services11 questions · 6 reporting periods · 0 of 11 challenging
UHS company page →

Calendar 2026 Q2

If this program is renewed for fiscal 26, would the sizing of the 2026 program be about the same

Regulation PolicyGuidance ReliabilityTranscript · FY2026 Q2 →
Show response

Filton was clear that no 2026 Florida benefit is booked or guided, and that other state programs are not expected to be material.

how we should think about the ramp of facility in San Antonio once it gets the CMS certification back

Regulation PolicyCapex InvestmentTranscript · FY2026 Q2 →
Show response

No timeline or ramp shape offered; Filton pointed to community demand as the reason he expects a fast ramp when it comes.

Calendar 2026 Q1

on professional fees, any trend updates and what are you doing to alleviate pressure, particularly in radiology?

Show response

Filton said professional fees tracking within guided high-single-digit range. Addressing hospital-based physician pressure through competitive RFPs and reducing expensive locums usage. Daily operational focus keeping fees manageable.

it seemed like rate outperformed even excluding the DPP. What drove the stronger price in the quarter, and why do you expect moderation for the rest of the year?

Show response

Filton said lower flu volume mechanically increased acuity mix (flu patients are lower-acuity). Also saw strong higher-acuity service line growth in cardiology, orthopedics, neurology. Expects more balanced contribution between rate and volume as year progresses.

Calendar 2025 Q4

For the programs that are not yet approved like Florida and I think maybe California, do you have any sense for where those approval processes stand with CMS?

Regulation PolicyRevenue GrowthTranscript · FY2025 Q4 →
Show response

Filton said Florida DPP ($45-50M) still expected approved but taking longer than anticipated; not in guidance. California DPP faces more hurdles and may need significant modification. Rural health program could provide modest benefit but relatively few UHS facilities carry rural designation.

Calendar 2025 Q3

is there any geographic variation to call out to highlight, particularly in some of your larger markets like Las Vegas?

DemandMacroeconomicTranscript · FY2025 Q3 →
Show response

Filton said Vegas performance consistent with overall portfolio despite tourist volume declines. Unemployment stable in market currently. Watching for potential ripple effects on economy but not seeing them yet. No other significant geographic variation.

Is there a way for us to think about how that breaks down the net benefit between acute and behavioral?

Show response

Filton said Nevada DPP increase is predominantly acute. Did not have Florida breakdown available during the call.

Calendar 2025 Q2

Are you able to quantify what that impact would be? Or just give us some sense for the drag on the same-store?

Geographic ExpansionRevenue GrowthTranscript · FY2025 Q2 →
Show response

Filton estimated West Henderson cannibalization at 50-60 basis points on same-facility adjusted admissions and a similar impact on revenues based on ZIP code analysis.

I wanted to see if there was anything to report with respect to professional fees and physician expenses

Show response

Filton said physician fees still tracking at ~5% growth guidance. New pressure from radiologists seeking subsidies after prior waves from ER doctors and anesthesiologists, but still within the guided range.

Calendar 2025 Q1

Any areas of particular outperformance to call out and sort of how you're feeling about the sustainability of that?

Cost PressureLabor MarketTranscript · FY2025 Q1 →
Show response

Filton confirmed $63M premium pay in Q1, consistent. Expense controls driven by labor stabilization, decelerated wage inflation, and active productivity management.

are you still expecting $997 million from the last disclosure? Or is that number changed at all?

Regulation PolicyGuidance ReliabilityTranscript · FY2025 Q1 →
Show response

Filton confirmed the $997M 2025 Medicaid supplemental payment expectation remains materially unchanged.

HCAHCA Healthcare7 questions · 7 reporting periods · 0 of 7 challenging
HCA company page →

Calendar 2026 Q2

You had mentioned that 3 divisions represented 50% of the impact Can you give some context

Geographic ExpansionRegulation PolicyTranscript · FY2026 Q2 →
Show response

Hazen named all three divisions explicitly and characterized the magnitude of the adjusted admission decline in those markets.

Calendar 2026 Q1

give us an update in terms of how things are playing out and if there's any signs that those markets are improving

DemandLabor MarketTranscript · FY2026 Q1 →
Show response

Sam explained demand exceeds expectations but labor costs are elevated due to workforce deficit in Western NC. Bottom line slightly behind expectations.

Calendar 2025 Q4

Can you give us a sense for how the exchange reforms and the subsidy expirations will impact the volume outlook?

DemandRegulation PolicyTranscript · FY2025 Q4 →
Show response

Mike confirmed exchange drag absorbed within 2-3% volume guide. Of those losing coverage, 15-20% to ESI, remainder uninsured with ~30% utilization decline. Exchange population uses ER more heavily than traditional commercial.

Calendar 2025 Q3

There was a little bit of an improvement this quarter versus last quarter. Sam just mentioned some of the seasonal dynamics. Can you give us a sense for some of the service lines

DemandCompetitive DynamicsTranscript · FY2025 Q3 →
Show response

Sam detailed outpatient strength in general surgery and urology, inpatient strength in neurosciences, orthopedics, and cardiac. Gynecology slightly down outpatient, neurosurgery modestly down inpatient.

Calendar 2025 Q2

there was a comment about a handful of markets that were underperforming. Can you give us some sense for the drivers of that underperformance

Competitive DynamicsDemandTranscript · FY2025 Q2 →
Show response

Sam noted 2 of 15 US divisions underperforming: one from competitive dynamics dislocating business, another from service mix change in Q2 expected to recover in H2. Declined to name specific markets.

Calendar 2025 Q1

do you see how system competitors behaving any differently in terms of their CapEx priorities or investments? Maybe that creates an opportunity for HCA

Competitive DynamicsMacroeconomicTranscript · FY2025 Q1 →
Show response

Sam noted no competitive behavior changes yet, but NIH funding pressure on academic centers could create opportunity. HCA's scale and diversification provide advantage over local competitors.

Calendar 2024 Q4

I want to see if there's any commentary on the California wildfires. And I know you've got a couple of facilities in the L.A. area, but any impact there to call out

Show response

Sam confirmed no impact from California wildfires. Ventura County facility was on alert but Palisades Fire did not reach their locations.

UNHUnitedHealth Group Incorporated2 questions · 2 reporting periods · 0 of 2 challenging
UNH company page →

Calendar 2026 Q3

I am just hoping you could give us a sense for how you would like to see those programs evolve over the next few years

Show response

Tim Noel called IDR awards at 10, 11 times Medicare rates excessive, and Bobby Hunter backed thoughtful Medicare Advantage modernization with program stability.

Calendar 2025 Q2

Can you get some detail on nature of those settlements? Are those mostly tied to value-based care contracts and Optum Health?

MarginCost PressureTranscript · FY2025 Q2 →
Show response

Rex said settlements span businesses including questionable receivables and disputed items dating back a year or more. Breakdown: about $500 million in Optum Health, $850 million in UHC, couple hundred million in Optum Insight, under $100 million in Optum Rx, plus about $100 million in corporate items.

HUMHumana1 question · 1 reporting period · 0 of 1 challenging
HUM company page →

Calendar 2025 Q4

Can you just remind us the proportion of MA members that are capitated?

Competitive DynamicsMarginTranscript · FY2025 Q4 →
Show response

George confirmed roughly one-third split: full risk, other value-based, and non-value-based/basic pay-for-performance. New member influx temporarily lowers paneled percentage at start of year, builds back up. Value-based partners wanting to expand significantly.

Challenge rate by company

Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.

CompanyQuestionsChallenge rate
UHS Universal Health Services110%none of 11 questions
HCA HCA Healthcare70%none of 7 questions
UNH UnitedHealth Group Incorporated2—Rate withheld: fewer than 3 questions
HUM Humana1—Rate withheld: fewer than 3 questions
  • UHS
    Universal Health Services · 11 questions
    0%none of 11 questions
  • HCA
    HCA Healthcare · 7 questions
    0%none of 7 questions
  • UNH
    UnitedHealth Group Incorporated · 2 questions
    —rate withheld: under 3 questions
  • HUM
    Humana · 1 question
    —rate withheld: under 3 questions

Activity by reporting period

Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.

Questions by calendar reporting period
Calendar periodQuestionsChallenge rateCompanies
2024 Q410%none of 1 question1
2025 Q130%none of 3 questions2
2025 Q240%none of 4 questions3
2025 Q330%none of 3 questions2
2025 Q430%none of 3 questions3
2026 Q130%none of 3 questions2
2026 Q230%none of 3 questions2
2026 Q310%none of 1 question1
  1. 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
  2. 2025 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
  3. 2025 Q24 questions · challenge rate 0% (none of 4 questions) · 3 companies
  4. 2025 Q33 questions · challenge rate 0% (none of 3 questions) · 2 companies
  5. 2025 Q43 questions · challenge rate 0% (none of 3 questions) · 3 companies
  6. 2026 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
  7. 2026 Q23 questions · challenge rate 0% (none of 3 questions) · 2 companies
  8. 2026 Q31 question · challenge rate 0% (none of 1 question) · 1 company

Topics

Topics tagged on this analyst’s questions.

  • Regulation Policy8
  • Demand6
  • Cost Pressure5
  • Competitive Dynamics4
  • Geographic Expansion2
  • Guidance Reliability2
  • Labor Market2
  • Margin2
  • Revenue Growth2
  • Macroeconomic2
Show all 12 topics
  • Capex Investment1
  • Pricing1